Analysts’ Weekly Ratings Changes for ACADIA Pharmaceuticals (ACAD)

ACADIA Pharmaceuticals (NASDAQ: ACAD) recently received a number of ratings updates from brokerages and research firms:

• 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by BMO Capital Markets from $34.00 to $36.00. They now have an “outperform” rating on the stock.
• 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by Stifel Nicolaus from $24.00 to $25.00. They now have a “hold” rating on the stock.
• 7/7/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $29.00 to $36.00. They now have an “outperform” rating on the stock.
• 6/30/2026 – ACADIA Pharmaceuticals was downgraded by HC Wainwright from “buy” to “hold”.
• 6/30/2026 – ACADIA Pharmaceuticals had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a “buy” rating on the stock.
• 6/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $37.00 price target on the stock.
• 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $32.00 to $35.00. They now have a “buy” rating on the stock.
• 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $36.00. They now have a “buy” rating on the stock.

Insider Transactions at ACADIA Pharmaceuticals

In other news, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the sale, the insider directly owned 24,509 shares in the company, valued at $519,100.62. The trade was a 18.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark C. Schneyer sold 3,506 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the completion of the sale, the executive vice president directly owned 66,145 shares of the company’s stock, valued at approximately $1,441,299.55. The trade was a 5.03% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 10,239 shares of company stock valued at $219,813 over the last ninety days. Company insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.